Bristol Should Have Opdivo First-Line Lung Cancer Data In Weeks
Executive Summary
With Opdivo sales up to $840m in the second quarter, Bristol execs once again make the case for trial strategy in the all-important first-line lung cancer indication and say they look forward to the CheckMate 026 data “in weeks not months.”
You may also be interested in...
Fourth EU Opdivo Approval Pending, But BMS Won't Gain Much
If as is expected the EU Commission rubber-stamps CHMP approval for BMS' Opdivo in classical Hodgkin lymphoma, it will be the first PD-1 inhibitor approved to treat a hematologic malignancy in the EU.
Does CheckMate 026 Take Bristol Out Of The End Game?
Failure of Bristol's Opdivo in patients with lower expression of PD-L-1 biomarker gives Merck's Keytruda a huge advantage in first-line lung cancer, and leaves market-leading Bristol to wait for combination data.
Merck Defends Its Offensive Strategy For Keytruda
Merck reports $314m for PD-1 inhibitor Keytruda in second quarter, mostly from melanoma indication, leaving it far behind Bristol's Opdivo. Pressed about its competitive strategy, company execs touted first-to-market advantage in first-line lung cancer and a "wall of data" that will protect in the future.